BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The business’s fifty day moving average price is $349.12 and its 200 day moving average price is $358.27.

Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize ...

Building a climate-controlled warehouse and logistics facility for United Therapeutics in North Carolina’s Research Triangle was a matter of power management and careful planning. The facility ...

United Therapeutics stock opened at $319.96 on Thursday. United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The company has a market capitalization of $14.28 billion ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...

Record Revenue Year: 2024 marked the third consecutive year of record-setting revenue for United Therapeutics. Overall Revenue Growth: Achieved almost 24% growth over the full year 2023.

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other best healthcare stocks for long-term investment. In the US, healthcare ...

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.